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Since the first publication of Framingham Risk Score in 
late 1950’s, derived from data obtained in an observational 
study to investigate cardiovascular risk factors, several other 
risk scores were created around the globe and they have 
been increasingly popular particularly in the last 10-20 years 
in cardiovascular medicine. The objective of a risk score is to 
individualize the risk for an individual patient with the use of 
functional equations based on multiple risk factors. Patients 
at high risk should be submitted to specific interventions to 
improve outcome.
Despite this huge increase in risk scoring development, 
most have not been implemented in clinical practice. In fact, 
many models showed low predictive performance (as assessed 
by their calibration and discrimination) and some are poorly 
reported or were developed using inappropriate methods. 
For that reason, international guidelines were developed for 
adequate development and reporting of prediction models.1 
For that objective to be fulfilled, it should include an adequate 
selection of the development cohort, adequate methodology 
for selection of variables and an adequate validation, both 
internal and external. In fact, external validation is particularly 
important because it tests the performance of a prediction 
model in a different independent patient cohort, where they 
usually perform less well. It can also allow comparison with 
other risk stratification tools. This step is essential for safe 
implementation in clinical practice. 
Risk stratification is important because populations 
are heterogeneous and present a large risk spectrum. 
Presently, there are very expensive and potent treatments, 
also with increased risk of adverse events, and thus, 
management decisions must be supported with risk 
stratification tools, although clinical judgment remains 
essential in these decisions. Unfortunately, in clinical 
practice, there is a misperception by the clinician that 
the use of individual risk indicators is sufficient to predict 
outcome and there is also a belief that the use of prediction 
rules may lead to overtreatment and that they are time 
consuming.2 This leads to the treatment–risk paradox that 
in many cases will result in inadequate treatment and poor 
outcome in patients at very high risk.
In this journal, Gil et al.3 present a paper where they 
compared several well-known risk stratification scores derived 
from both randomized clinical trial and registries.3 They also 
included some scores that were developed for other purposes 
of risk stratification in cardiovascular medicine. The scores 
that better predicted in-hospital mortality were GRACE, 
ACTION-Registry-GWTG and ProACS, but for long-term 
outcome, none of the studied scores was appropriate. This is a 
retrospective analysis performed in 1,452 patients admitted with 
an acute coronary syndrome (ACS), 45.1% with ST-elevation 
myocardial infarction, with in-hospital mortality of 6.5% and 
9.9% of death / non-fatal ACS in a one-year follow-up.
ProACS risk score was developed with a very specific purpose 
of providing a very easy and simple risk score, with immediate 
variables, that could be applied early, in the first medical contact, 
to better decide on patient management strategy.4 ProACS was 
developed from one of the largest registries worldwide, the 
Portuguese Registry of Acute Coronary Syndromes, with more 
than 45,000 patients included.5 In the development study, 
this score showed good discrimination in all the study cohorts 
(development, internal and external validation), and similar 
results were also reported in an independent external validation 
cohort.4.6 Calibration was adequate in all these studies. Results 
were, however, slightly worst, compared to GRACE risk score 
and a recommendation was included that this should be used 
only as an early risk stratification score, with GRACE risk score to 
be used later after hospital admission. Surprisingly, in the present 
study, discrimination of ProACS was even high, with similar 
c-statistics when compared to the most potent risk stratification 
scores, but calibration was not adequate, particularly in the 
non-ST elevation ACS cohort.
One important finding is that ProACS risk score is very 
similar to C-ACS risk score;7 however, this one was developed 
in Canada with different patient characteristics, and had very 
low discrimination in the Portuguese population, stressing the 
importance of regional external validation studies. Also, risk 
scores developed from randomized clinical trials were less useful 
compared to risk scores developed from registries, in cohorts 
more representative of real-world populations. Clinical trials 
cohort is very selective, limiting extrapolation for general 
populations, patients are usually younger and healthier, with a 
lower rate of comorbidities and clinical trials do not reproduce 
practices and strategies used in most centres. For that reason, the 
external validity of models derived from clinical trials is usually 
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The main objective of ProACS risk score is to immediately 
stratify the risk in patients with ACS to decide on the adequate 
management and thus its main objective is the short-term 
outcome. Results in longer-term follow up were not adequate. 
For long-term outcome, the inclusion of other variables, such 
as renal function, troponins and others are also important.
What should not be forgotten is that for each risk 
stratification score, impact studies should also be performed 
after external validation. In fact, external validity does not 
mean that beneficial clinical effects will be obtained when 
we use a risk score and it does not give information regarding 
the possible adverse events. Impact studies are essential 
and should be studied separately from development and 
validation, preferably in randomized clinical trials and they 
are usually not performed. From the above, researchers should 
spend more time on validation and assessing the impact of 
existing models instead of developing more models that will 
most likely never be used in clinical practice. This should be 
the next step to definitely support the use of ProACS risk score 
in clinical practice.
From the results presented in this study, ProACS risk score 
will probably be soon implemented in clinical practice, due 
to the easy and simple application in clinical practice and 
high discrimination presented but impact studies are needed.
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